Related by context. All words. (Click for frequent words.) 75 relapsing remitting multiple sclerosis 73 relapsing remitting 67 RRMS 64 IBS C 63 relapsing multiple sclerosis 63 indolent NHL 63 symptomatic BPH 63 relapsing MS 62 recurrent glioblastoma multiforme 62 systemic lupus erythematosus 62 relapsing remitting MS RRMS 62 relapsing forms 62 chronic plaque psoriasis 62 SJIA 61 dirucotide MBP# 61 primary hypercholesterolemia 61 chronic lymphocytic leukemia CLL 61 metastatic renal cell carcinoma 61 tocilizumab 61 myelodysplastic syndrome MDS 61 RoACTEMRA 61 lupus nephritis 61 COPAXONE R 61 recurrent glioblastoma 60 severe psoriasis 60 homozygous familial hypercholesterolemia 60 Crohn disease 60 AGILECT ® 60 heavily pretreated 60 AGILECT R 60 partial onset seizures 60 eosinophilic asthma 60 bendamustine 60 leukemia AML 60 HER2 positive metastatic breast 60 anakinra 60 rheumatoid arthritis RA 60 metastatic hormone refractory 60 TORISEL 60 generalized seizures 60 relapsed refractory multiple myeloma 60 plaque psoriasis 59 lacosamide 59 superficial bladder cancer 59 Relapsing remitting MS 59 renal cell carcinoma 59 dirucotide 59 COPAXONE ® 59 Rheumatoid Arthritis RA 59 Hodgkin lymphoma HL 59 rheumatoid arthritis psoriatic arthritis 59 adalimumab 59 Neovascular AMD 59 active ankylosing spondylitis 59 monotherapy 59 phase IIb clinical 59 systemic lupus erythematosus SLE 59 recurrent ovarian cancer 59 Betaferon ® 59 Vimpat ® 59 juvenile idiopathic arthritis 59 hepatitis C genotype 59 glioblastoma multiforme GBM 59 adult chronic ITP 59 Amrubicin 59 beta interferon 59 RRMS patients 59 ACTEMRA TM 58 Etanercept 58 ACTEMRA 58 TEAEs 58 interferon beta 1a 58 CHOP chemotherapy 58 Cladribine Tablets 58 diabetic neuropathic pain 58 mRCC 58 PD LID 58 teriflunomide 58 cabazitaxel 58 acute myelogenous leukemia AML 58 chronic HCV infection 58 desvenlafaxine succinate 58 SCH # 58 aprepitant 58 autoantibody positive 58 pomalidomide 58 acute myeloid leukemia AML 58 PREZISTA r 58 B CLL 58 HER2 positive breast cancer 58 colorectal liver metastases 58 fingolimod 58 Cladribine tablets 58 heterozygous FH 58 cholinesterase inhibitor 58 invasive candidiasis 58 refractory multiple myeloma 58 phase IIb trial 58 sunitinib 58 relapsed MM 58 refractory epilepsy 58 MabCampath 57 Gleevec resistant 57 Chronic lymphocytic leukemia 57 metastatic renal cell 57 juvenile idiopathic arthritis JIA 57 abatacept 57 placebo controlled clinical 57 brain metastases 57 biliary tract cancer 57 opioid induced constipation 57 CRVO 57 methotrexate MTX 57 pancreatic NET 57 YONDELIS 57 proliferative diabetic retinopathy 57 recurrent genital herpes 57 pazopanib 57 hypercalcemia 57 lumiliximab 57 interferon beta 1b 57 sorafenib 57 oral vancomycin 57 postherpetic neuralgia 57 Adalimumab 57 primary generalized tonic 57 mycophenolate mofetil 57 adalimumab Humira 57 Laquinimod 57 Acute Myelogenous Leukemia AML 57 recurrent malignant glioma 57 leukemia CLL 57 castration resistant prostate cancer 57 chlorambucil 57 non metastatic osteosarcoma 57 phase IIb study 57 sunitinib malate 57 hepatocellular cancer 57 stage IIIB 57 visilizumab 57 retinal vein occlusion 57 fibromyalgia syndrome 57 ZOLINZA 57 IV melanoma 57 metastatic RCC 57 anterior uveitis 57 Arranon 57 post herpetic neuralgia PHN 57 hypoparathyroidism 57 AA amyloidosis 57 hepatocellular carcinoma HCC 57 vandetanib 57 PEGylated interferon beta 1a 57 levodopa therapy 57 leukemia ALL 57 interferon therapy 57 cilengitide 57 progressive PsA 57 HeFH 57 refractory AML 57 rheumatoid arthritis 57 metastatic bladder 57 antihypertensive therapy 57 Parkinson disease PD 57 Vaprisol 57 rufinamide 57 LIALDA 57 atypical antipsychotic medication 57 baminercept 57 stable angina pectoris 57 proliferative retinopathy 57 ankylosing spondylitis 56 T2DM 56 chronic GVHD 56 riociguat 56 gastrointestinal stromal tumor GIST 56 anti TNF 56 tolvaptan 56 receptor tyrosine kinase inhibitor 56 HBeAg negative patients 56 alemtuzumab 56 PsA 56 PEGINTRON TM 56 intractable epilepsy 56 CIMZIA ™ 56 ulcerative colitis 56 icatibant 56 Lennox Gastaut syndrome 56 ADAGIO study 56 TEMODAL 56 metastatic colorectal carcinoma 56 ponatinib 56 immune thrombocytopenic purpura ITP 56 onset seizures 56 allopurinol 56 Major Depressive Disorder 56 gastrointestinal stromal tumors 56 Relapsing Remitting Multiple Sclerosis 56 Myelodysplastic Syndrome MDS 56 basal cell carcinoma BCC 56 forodesine 56 alemtuzumab treated 56 Plicera 56 Cimzia ® certolizumab pegol 56 cladribine 56 Fludara 56 atherothrombotic events 56 chronic angina 56 VaD 56 acute coronary syndromes ACS 56 panitumumab Vectibix 56 amrubicin 56 opioid induced constipation OIC 56 relapsed CLL 56 imatinib resistant 56 rilonacept 56 INVEGA ® 56 neurogenic orthostatic hypotension 56 DMARD therapy 56 trials RCTs 56 lymphoma CTCL 56 diabetic gastroparesis 56 protease inhibitor PI 56 placebo dexamethasone 56 carcinoid tumors 56 aHUS 56 castrate resistant prostate cancer 56 IV metastatic melanoma 56 rasagiline 56 chronic ITP patients 56 KRAS mutations occur 56 metastatic colorectal cancer 56 biologic therapy 56 chronic hepatitis B. 56 pegylated interferon alfa 2a 56 evaluating tivozanib 56 hepatic encephalopathy HE 56 PRTX 56 Alemtuzumab 56 chronic hepatitis C. 56 infliximab 56 Traficet EN 56 azacitidine 56 macroalbuminuria 56 natalizumab 56 efalizumab 56 Diabetic Macular Edema 56 neovascular AMD 56 chronic myeloid leukemia CML 56 mcg albinterferon alfa 2b 56 Torisel 56 HBeAg positive 56 diagnosed Ph + 56 hepatocellular carcinoma 56 AVONEX ® 56 DPNP 56 medullary thyroid cancer 56 Ph + ALL 56 unstable angina UA 56 anti EGFR antibody 56 canakinumab 56 Teriflunomide 56 cisplatin chemotherapy 56 de novo kidney transplant 56 Chronic Lymphocytic Leukemia CLL 56 evaluable subjects 56 metastatic malignant melanoma 56 opioid induced bowel dysfunction 56 neurological manifestations 56 octreotide LAR 56 Phase 2b trial 56 rosuvastatin #mg 56 ankylosing spondylitis AS 56 etanercept 56 Azilect ® 56 everolimus tablets 56 alefacept 56 major depressive disorder 56 acute coronary syndrome 56 Hepatocellular Carcinoma HCC 56 Scale EDSS 56 docetaxel chemotherapy 56 follicular lymphoma FL 56 inhibitor RG# 56 GnRH agonists 55 subsyndromal 55 rotigotine 55 idiopathic Parkinson disease 55 BCG refractory 55 REMICADE ® 55 chronic myeloid 55 refractory CLL 55 moderate renal impairment 55 virus HCV infection 55 Chronic Idiopathic Constipation 55 evaluable patients 55 SUTENT 55 antibody MAb 55 risperidone Risperdal 55 active comparator 55 antiepileptic drugs 55 Phase Ib clinical 55 psoriatic arthritis PsA 55 8mg/kg 55 rituximab Rituxan 55 TNF alpha inhibitor 55 leukemia APL 55 Restless Legs Syndrome RLS 55 VFEND 55 cell lymphoma CTCL 55 APTIVUS r 55 liver metastases 55 primary immunodeficiency PI 55 ACZ# 55 CIMZIA TM 55 AA Amyloidosis 55 NOXAFIL 55 idiopathic pulmonary fibrosis IPF 55 VAPRISOL 55 null responders 55 systemic ALCL 55 Pegasys ® 55 relapsed ovarian cancer 55 FSAD 55 schizophrenia CIAS 55 demyelinating 55 sorafenib tablets 55 EVIZON 55 Vandetanib 55 cinacalcet 55 temsirolimus 55 acute promyelocytic leukemia 55 lubiprostone 55 dopaminergic therapy 55 pulmonary hypertension PH 55 relapsed refractory 55 donepezil 55 paroxysmal AF 55 glatiramer acetate 55 basal cell nevus syndrome 55 mycosis fungoides 55 Doxil ® 55 HCV SPRINT 55 Glioblastoma Multiforme 55 Raptiva ® 55 Natalizumab 55 BRIM2 55 venlafaxine XR 55 Cimzia ® 55 KRAS wild 55 plus methotrexate 55 fluticasone furoate 55 clobazam 55 generalized epilepsy 55 HuMax CD4 55 T1DM 55 receiving golimumab 55 partial remissions 55 multiple sclerosis MS 55 Bezielle 55 TYKERB 55 GSK# [001] 55 refractory gout 55 hyperphenylalaninemia HPA due 55 partial onset 55 virological failure 55 antiarrhythmic drug 55 abiraterone 55 Velcade bortezomib 55 nitazoxanide 55 randomized placebo controlled 55 hour bronchodilation 55 hormone refractory prostate cancer 55 pregabalin 55 pancreatic neuroendocrine tumors 55 regorafenib 55 acute myeloid leukemia 55 olmesartan 55 acute leukemias 55 Betaferon R 55 refractory CTCL 55 actinic keratosis 55 secondary hyperparathyroidism 55 Cutaneous T 55 standard chemotherapy regimens 55 chronic migraine 55 diagnosed glioblastoma multiforme 55 antiepileptic drug 55 blinded placebo controlled 55 Keppra ® 55 metastatic GIST 55 Zavesca ® 55 double blinded placebo 55 citalopram 55 pancreatic adenocarcinoma 55 intravenous RSD# 55 dose escalation clinical 55 rotigotine transdermal patch 55 TNF inhibitors 55 diarrhea predominant irritable 55 mapatumumab 55 Aryplase 55 Cinquil 55 cutaneous T cell 55 desvenlafaxine 55 hoFH 55 dexamethasone Decadron 55 chronic HBV infection 55 Peginterferon alfa 2b 55 oral FTY# 55 TTF Therapy 55 antiretroviral naïve 55 Chronic Myelogenous Leukemia CML 55 CAELYX 55 diagnosed multiple myeloma 55 Irinotecan 55 Ilaris 55 ischemic stroke 55 Lu AA# 55 SHPT 55 MIRAPEX ER 55 pramipexole 55 Rebif ® 55 LHRH analogues 55 recurrent NSCLC 55 erlotinib Tarceva ® 55 mCRC 55 NYHA Class II 55 INCB# [003] 55 Phase III randomized 55 TMC# r 55 cytogenetic responses 55 pulmonary arterial hypertension 55 moderate plaque psoriasis 55 C1 INH deficiency 55 pegylated interferon alpha 55 PAOD 55 weekly intravenous infusions 55 methotrexate monotherapy 55 grade gliomas 55 adjunctive placebo 54 stable angina 54 chemoradiotherapy 54 DMARD 54 placebo controlled Phase 54 progressive psoriatic arthritis 54 tenofovir emtricitabine 54 mild cognitive impairment 54 carcinoid syndrome 54 Relapsing remitting 54 smoldering multiple myeloma 54 darapladib 54 constipation OIC 54 sJIA 54 subependymal giant cell 54 antiepileptic drugs AEDs 54 INCB# [001] 54 post operative ileus 54 immunomodulatory therapy 54 advanced hepatocellular carcinoma 54 Phenoptin 54 LUX Lung 54 lomitapide 54 Rilonacept 54 Pemetrexed 54 dosage regimens 54 EGFR mutations 54 HER2 positive 54 subcutaneously administered 54 taxane chemotherapy 54 ataluren 54 acute gout 54 NATRECOR R 54 chronic HCV 54 BRAF inhibitor 54 events AEs 54 diarrhea predominant IBS 54 metastatic kidney 54 SNT MC# 54 glioblastoma 54 CYT# potent vascular disrupting 54 Ophena TM 54 interferon alfa 2b 54 tarenflurbil 54 severe exacerbations 54 adjunctive ABILIFY 54 somatostatin analog 54 acne vulgaris 54 myelofibrosis 54 synthetic retinoid 54 Mitoxantrone 54 myelodysplastic syndromes 54 infliximab Remicade 54 dose cohorts 54 idarubicin 54 arthritis PsA 54 nilotinib 54 fludarabine 54 Increlex R 54 IV NSCLC 54 Diamyd ® 54 carbidopa levodopa 54 Systemic Juvenile Idiopathic 54 Syndrome LEMS 54 BRIM3 54 trans retinoic acid ATRA 54 antiretroviral naive 54 Zolinza 54 hyperammonemia 54 eculizumab 54 systemic lupus 54 methylnaltrexone 54 Follicular lymphoma 54 refractory NSCLC 54 Chronic Myeloid Leukemia 54 carboplatin paclitaxel 54 elevated ALT 54 homozygous FH 54 achieved ACR# 54 SCIg 54 epithelial ovarian cancer 54 perampanel 54 bone metastases 54 raltegravir 54 recurrent GBM 54 Phase IIb trial 54 squamous histology 54 irritable bowel syndrome IBS 54 EDSS score 54 PSADT 54 6R BH4 54 Follicular Lymphoma 54 decitabine 54 temozolomide 54 KRAS mutant tumors 54 mg kg dose 54 Certolizumab pegol 54 phase IIa clinical 54 paricalcitol 54 TNF antagonist 54 Acute Myeloid Leukemia AML 54 familial amyloidotic polyneuropathy FAP 54 beta 1a 54 pegylated alpha interferon 54 Tamibarotene 54 dacarbazine 54 mesalazine 54 pediatric Crohn disease 54 rheumatic disease 54 nonmetastatic prostate cancer 54 HBeAg negative 54 HAART regimen 54 metastatic castration resistant 54 HCV RESPOND 2 54 dosing cohorts 54 estramustine 54 iniparib 54 Fludara ® 54 placebo controlled 54 dopamine agonist 54 intravenous cyclophosphamide 54 infantile spasms 54 Herceptin trastuzumab 54 MCyR 54 NMIBC 54 metastatic CRC 54 pegaptanib 54 Hypoactive Sexual Desire Disorder 54 low dose cytarabine 54 bipolar depression 54 pramlintide 54 relapsed SCLC 54 Phase IIa trial 54 GW# [003] 54 neuropsychiatric symptoms 54 Flu Cy 54 DMARDs 54 relapsed Hodgkin lymphoma 54 mitoxantrone 54 conventional DMARDs 54 tanespimycin 54 liposomal doxorubicin 54 levetiracetam 54 refractory metastatic colorectal cancer 54 HNSCC 54 levodopa 54 Jevtana 54 prostate cancer CRPC 54 mixed dyslipidemia 54 peginterferon alfa 2a 54 MBP# dirucotide 54 pediatric malignancies 54 Juvenile Idiopathic Arthritis 54 vismodegib 54 oral rivaroxaban 54 hypercholesterolemic patients 54 nonsmall cell lung cancer 54 pegylated liposomal doxorubicin 54 mg administered orally 54 heavily pretreated patients 54 generalized anxiety disorder GAD 54 remission induction 54 mCRC acneform rash 54 cutaneous T 54 chronic neuropathic pain 54 diabetes mellitus DM 54 heFH 54 RECIST criteria 54 patients evaluable 54 blinded randomized placebo controlled 54 progressive neurodegenerative disorder 54 ocrelizumab 54 systemic juvenile idiopathic 54 post herpetic neuralgia 54 LEXIVA r 54 intravenous bisphosphonates 54 rituximab refractory 54 evaluable 54 ofatumumab 54 Mylotarg 54 iniparib BSI 54 Burkitt lymphoma 54 virological response 54 Miraxion 54 irbesartan 54 relapsed multiple myeloma 54 UCB Cimzia 54 PEGINTRON 54 stage IIIB IV 54 FOLFOX6 54 sulfasalazine 54 MPS VI 54 Relapsing Remitting MS 54 Hydroxyurea 54 hereditary antithrombin deficiency 54 chronic ITP 54 bortezomib 54 TMS Therapy 54 chronic lymphocytic leukemia 54 papillary renal cell carcinoma 54 IMGN# 54 NSCLC 54 briakinumab 54 Acute Coronary Syndromes ACS 54 mg BID 54 controlled multicenter 54 Campath alemtuzumab 54 interferon beta therapy 54 romiplostim 54 metastatic colon cancer 54 SEROQUEL XR 54 phenoxodiol 54 oral methylnaltrexone 54 lintuzumab SGN 54 Nexavar ® 54 HuLuc# 54 Ulcerative Colitis 54 Myelofibrosis 54 MBP# [001] 54 DLBCL 53 Firazyr 53 malignant pleural mesothelioma 53 dose cytarabine 53 Telintra 53 follicular lymphoma 53 ADPKD 53 histologically confirmed 53 polyarticular 53 Cariprazine 53 MGd 53 abiraterone acetate 53 metastatic HRPC 53 recurrent glioma 53 bone metastasis 53 LHRH agonists 53 hepatic encephalopathy 53 ritonavir boosted 53 dose regimens 53 severe idiopathic Restless 53 de novo AML 53 MIRAPEX 53 non squamous NSCLC 53 ribavirin therapy 53 hypersensitivity reaction 53 tumor shrinkage 53 functional dyspepsia 53 anemia hemoglobin 53 galiximab 53 HUMIRA 53 pertuzumab 53 treatment naïve genotype 53 CMV disease 53 ribavirin RBV 53 dosing cohort 53 sorafenib Nexavar 53 nabilone 53 Idiopathic Pulmonary Fibrosis 53 Gleevec imatinib 53 amnestic mild cognitive impairment 53 elotuzumab 53 OHR/AVR# 53 registrational 53 INTEGRILIN R 53 Chronic myeloid leukemia 53 CTAP# Capsules 53 metreleptin 53 Increlex ® 53 myeloproliferative diseases 53 unresectable 53 axitinib 53 Complicated Skin 53 acute ischemic stroke 53 Kit CD# positive 53 HUMIRA adalimumab 53 thyrotoxicosis 53 Cell Lymphoma CTCL 53 unresectable stage 53 Parkinson Disease PD 53 Vimpat R 53 calcineurin inhibitor 53 ischemic strokes 53 idiopathic thrombocytopenic purpura ITP 53 recurrent VTE 53 rimonabant #mg 53 multicenter randomized placebo controlled 53 differentiated thyroid 53 achieved PASI 53 AZILECT R 53 nonmelanoma skin cancers 53 IFN beta 53 CsA 53 grade glioma 53 DAPT 53 T#I mutation 53 rituximab 53 systemic corticosteroid 53 BPH symptoms 53 eltrombopag 53 anti arrhythmic drug 53 dasatinib 53 IIIB NSCLC 53 sorafenib Nexavar ® 53 phase IIa 53 GBM tumors 53 Acute Myeloid Leukaemia AML 53 ancrod 53 REVLIMID ® 53 stage IIIb 53 JANUVIA 53 fenretinide 53 Degarelix 53 ximelagatran 53 Alzhemed TM 53 refractory myeloma 53 FAMPYRA 53 multiple myeloma MM 53 CYPHER Stent 53 ALT flares 53 osteosarcomas 53 ALA PDT 53 imatinib therapy 53 triptans 53 diabetic nephropathy 53 geographic atrophy 53 anti angiogenic therapy 53 Ankylosing spondylitis 53 AEGR 53 Crohn disease CD 53 Raptiva R 53 small lymphocytic lymphoma 53 malignant lymphoma 53 advanced metastatic prostate 53 cutaneous melanoma 53 irinotecan chemotherapy 53 elevated triglyceride levels 53 Tyrima 53 Aflibercept 53 MabThera Rituxan 53 Tocilizumab 53 severe hypercholesterolemia 53 nonmelanoma skin cancer 53 gemcitabine chemotherapy 53 lamotrigine 53 EXJADE 53 EDSS scores 53 FTY# 53 lupus erythematosus 53 tofacitinib 53 pleural mesothelioma 53 coinfected 53 vidofludimus 53 unstable angina 53 hormone deprivation 53 ischemic cardiomyopathy 53 peginterferon 53 lamivudine 53 CIMZIA TM certolizumab pegol 53 plus dexamethasone 53 intermittent claudication 53 OADs 53 metastatic CRPC 53 Wet AMD 53 MGUS 53 Major Depressive Disorder MDD 53 REYATAZ r arm 53 Chronic lymphocytic leukemia CLL 53 Taxotere ® 53 venlafaxine ER 53 LHON 53 clinically meaningful improvements 53 alemtuzumab Campath 53 boosted protease inhibitor 53 annualized relapse 53 golimumab 53 alvespimycin 53 Median survival 53 Dacogen injection 53 naïve HCV 53 hereditary deficiency 53 tasocitinib 53 deletion 5q 53 randomized #:#:# 53 SCCHN 53 AVODART 53 goserelin 53 overactive bladder OAB 53 multiple myeloma 53 vemurafenib 53 AZILECT 53 candidemia 53 Wilms tumor 53 Golimumab 53 virologic failure 53 methimazole 53 Rezular 53 hematological malignancy 53 metastatic lung cancer 53 4mg/kg 53 non alcoholic steatohepatitis 53 histologies 53 ARIXTRA 53 soft tissue sarcomas 53 PREZISTA ritonavir 53 gemcitabine Gemzar 53 cutaneous squamous cell carcinoma 53 paliperidone ER 53 pyridostigmine 53 dasatinib Sprycel 53 Severe Primary IGFD 53 acute lymphoblastic 53 Dapagliflozin 53 APTIVUS 53 familial hypercholesterolemia 53 anthracyclines taxanes 53 acyclovir Lauriad R 53 laquinimod 53 LymphoStat B 53 cediranib 53 chemotherapy regimen 53 Phase 2a trial 53 medically inoperable 53 Omacetaxine 53 alkylating agent 53 severely active polyarticular 53 Folfox 53 Tasimelteon 53 Crizotinib 53 tamoxifen therapy 53 nonalcoholic steatohepatitis NASH 53 Myelodysplastic Syndrome 53 Tolvaptan 53 malignant gliomas 53 metastatic carcinoid 53 basiliximab 53 refractory APL 53 solid tumors 53 MMX mesalamine 53 allodynia 53 evaluating Xcytrin 53 Certican 53 LAF# 53 BAY #-# 53 hematologic toxicity 53 ORACLE MS 53 definite stent thrombosis 53 #mg/day [001] 53 TREANDA 53 standard chemotherapy regimen 53 grade dysplasia 53 impaired glucose tolerance 53 induced macular edema 53 RLAI 53 ONGLYZA 53 Alzheimer Disease AD 53 dose dose escalation 53 prostate cancer CaP 53 Tavocept 53 pancreatic insufficiency 53 GAMMAGARD 53 ER CHOP 53 TMC# C# 53 Enzastaurin 53 Fingolimod 53 thymoma 53 Phase III placebo controlled 53 crizotinib PF # 53 VICTRELIS 53 CANCIDAS 53 lymphomas 53 refractory cutaneous T 53 mg dose 53 Cell Lymphoma 53 Nexavar sorafenib 53 MELAS 53 diabetes mellitus 53 chronic inflammatory demyelinating 53 certolizumab 53 Azedra 53 chronic myelogenous leukemia CML 53 Abilify aripiprazole 53 FOLFIRI 53 glitazone 53 viral kinetics 53 metastatic malignant 53 rFVIIa 53 refractory ovarian cancer 53 adjunctive therapy 53 Sycrest 53 metastatic cancer 53 Evoltra TM 53 myasthenia gravis MG 53 Castration Resistant Prostate Cancer 52 serum phosphate 52 vWD 52 HSDD 52 gastrointestinal stromal tumors GIST 52 metastatic melanoma 52 colorectal adenoma 52 CCR5 tropic HIV 52 plus gemcitabine 52 dose cohort 52 glioblastoma multiforme 52 refractory anaplastic astrocytoma 52 investigational compound 52 CTEPH 52 tegaserod 52 methotrexate therapy 52 phase Ib clinical 52 ISENTRESS 52 Glioblastoma 52 indolent lymphoma 52 IIa trial 52 knee osteoarthritis OA 52 elacytarabine 52 clonic seizures 52 Clolar 52 dose escalation phase 52 entecavir 52 Glioblastoma Multiforme GBM 52 gefitinib Iressa 52 prostate cancer HRPC 52 LEXIVA 52 chronic granulomatous disease 52 receptor inhibitor 52 Navelbine 52 severe oral mucositis 52 Sprycel dasatinib 52 anti leukemic 52 placebo controlled studies 52 cetuximab 52 ELOXATIN 52 telaprevir dosing 52 Zomig 52 TELINTRA 52 hyperuricemia 52 xanthine oxidase inhibitor 52 comparator arm 52 daunorubicin 52 juvenile myoclonic epilepsy 52 intravenous dosing 52 disease modifying antirheumatic 52 IV bisphosphonates 52 hepatocellular carcinomas 52 severe plaque psoriasis 52 melphalan prednisone 52 TYZEKA 52 relapsed AML 52 debilitating autoimmune 52 esophagitis 52 Dasatinib 52 Phase 2b study 52 doxorubicin HCl liposome injection 52 3TC lamivudine Epivir 52 eszopiclone 52 selective modulator 52 paroxysmal nocturnal hemoglobinuria PNH 52 MACUGEN 52 dimebon 52 neuropathic pain